Clinical outcome and risk factors for failure in late acute prosthetic joint infections treated with debridement and implant retention

Clinical outcome and risk factors for failure in late acute prosthetic joint infections treated with debridement and implant retention

Marjan Wouthuyzen-Bakker , Marine Sebillotte , Jose Lomas , Adrian Taylor , Eva Benavent Palomares , Oscar Murillo , Javad Parvizi , Noam Shohat , Javier Cobo Reinoso , Rosa Escudero Sánchez , Marta Fernandez-Sampedro , Eric Senneville , Kaisa Huotari , José Maria Barbero Allende , Joaquín Garcia-Cañete , Jaime Lora-Tamayo , Matteo Carlo Ferrari , Danguole Vaznaisiene , Erlangga Yusuf , Craig Aboltins , Rihard Trebse , Mauro José Salles , Natividad Benito , Andrea Vila , Maria Dolores Del Toro , Tobias Siegfried Kramer , Sabine Petersdorf , Vicens Diaz-Brito , Zeliha Kocak Tufan , Marisa Sanchez , Cédric Arvieux , Alex Soriano , on behalf of the ESCMID Study Group for Implant-Associated Infections (ESGIAI)

PII: S0163-4453(18)30241-X
DOI: https://doi.org/10.1016/j.jinf.2018.07.014
Reference: YJINF 4141

To appear in: *Journal of Infection*

Received date: 21 December 2017
Revised date: 5 July 2018
Accepted date: 19 July 2018

Please cite this article as: Marjan Wouthuyzen-Bakker , Marine Sebillotte , Jose Lomas , Adrian Taylor , Eva Benavent Palomares , Oscar Murillo , Javad Parvizi , Noam Shohat , Javier Cobo Reinoso , Rosa Escudero Sánchez , Marta Fernandez-Sampedro , Eric Senneville , Kaisa Huotari , José Maria Barbero Allende , Joaquín Garcia-Cañete , Jaime Lora-Tamayo , Matteo Carlo Ferrari , Danguole Vaznaisiene , Erlangga Yusuf , Craig Aboltins , Rihard Trebse , Mauro José Salles , Natividad Benito , Andrea Vila , Maria Dolores Del Toro , Tobias Siegfried Kramer , Sabine Petersdorf , Vicens Diaz-Brito , Zeliha Kocak Tufan , Marisa Sanchez , Cédric Arvieux , Alex Soriano , on behalf of the ESCMID Study Group for Implant-Associated Infections (ESGIAI), Clinical outcome and risk factors for failure in late acute prosthetic joint infections treated with debridement and implant retention, *Journal of Infection* (2018), doi: https://doi.org/10.1016/j.jinf.2018.07.014

Clinical outcome and risk factors for failure in late acute prosthetic joint infections treated with debridement and implant retention

Marjan Wouthuyzen-Bakker[a,*], Marine Sebillotte[b], Jose Lomas[c], Adrian Taylor[c], Eva Benavent Palomares[d], Oscar Murillo[d], Javad Parvizi[e], Noam Shohat[e,f], Javier Cobo Reinoso[g], Rosa Escudero Sánchez[g], Marta Fernandez-Sampedro[h], Eric Senneville[i], Kaisa Huotari[j], José Maria Barbero Allende[k], Joaquín Garcia-Cañete[l], Jaime Lora-Tamayo[m], Matteo Carlo Ferrari[n], Danguole Vaznaisiene[o], Erlangga Yusuf[p], Craig Aboltins[q,r], Rihard Trebse[s], Mauro José Salles[t], Natividad Benito[u], Andrea Vila[v], Maria Dolores Del Toro[w], Tobias Siegfried Kramer[x,y], Sabine Petersdorf[z], Vicens Diaz-Brito[aa], Zeliha Kocak Tufan[bb], Marisa Sanchez[cc], Cédric Arvieux[b,dd], Alex Soriano[ee]; on behalf of the ESCMID Study Group for Implant-Associated Infections (ESGIAI)

[a]Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, the Netherlands
[b]Department of Infectious Diseases and Intensive Care Medicine, Rennes University Hospital, Rennes, France.
[c]Bone Infection Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, England.
[d]Infectious Disease Service. IDIBELL-Hospital Universitari Bellvitge, Barcelona, Spain.
[e]Rothman Institute at Thomas Jefferson University Hospital, Philidelphia, United States.
[f]Department of Orthopaedic Surgery, Tel Aviv University, Tel Aviv, Israel.
[g]Servicio de Enfermedades Infecciosas. Hospital Universitario Ramón y Cajal. IRYCIS. Madrid, Spain
[h]Infectious Diseases Unit, Department of Medicine, Hospital Universitario Marques de Valdecilla-IDIVAL, Cantabria, Spain.
[i]Department of Infectious Diseases, University Hospital Gustave Dron Hospital, Tourcoing, France.
[j]Inflammation center, Infectious Diseases, Peijas Hospital, Helsinki University Hospital and University of Helsinki, Finland.
[k]Department of Internal Medicine. Hospital Universitario Principe de Asturias, Madrid, Spain.
[l]Department of Internal Medicine-Emergency, IIS-Fundación Jiménez Díaz, UAM, Av. Reyes Católicos 2, 28040 Madrid, Spain.
[m]Department of Internal Medicine. Hospital Universitario 12 de Octubre. Instituto de Investigación i+12. Madrid, Spain
[n]Department of Prosthetic Joint Replacement and Rehabilitation Center, Humanitas Research Hospital and Humanitas University, Milan, Italy.
[o]Department of Infectious Diseases, Medical Academy, Lithuanian University of Health Sciences, Kaunas Clinical Hospital, Kaunas, Lithuania
[p]Department of Microbiology, Antwerp University Hospital (UZA), University of Antwerp, Edegem, Belgium.
[q]The Department of Infectious Diseases, Northern Health, Melbourne, Australia.
[r]The University of Melbourne, Northern Clinical School, Melbourne, Australia.
[s]Service for Bone Infections, Valdoltra Orthopaedic Hospital, Ankaran, Slovenia.
[t]Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brasil.
[u]Infectious Diseases Unit, Department of Internal Medicine, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
[v]Servicio de Infectología, Hospital Italiano de Mendoza, Mendoza, Argentina.
[w]Unidad Clínica de Enfermedades Infecciosa y Microbiología. Universidad de Sevilla. Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain.
[x]Nationales Referenzzentrum für Surveillance von nosokomialen Infektionen am Institut für Hygiene und Umweltmedizin Charité-Universitätsmedizin, Berlin, Germany.
[y]LADR, GmbH MVZ, Neuruppin, Germany.
[z]Institute of Medical Microbiology and Hospital Hygiene University Hospital, Heinrich-Heine-University. Düsseldorf, Germany.
[aa]Infectious Diseases Unit, Parc Sanitari Sant Joan de Deu, Sant Boi, Barcelona, Spain.
[bb]Infectious Diseases and Clinical Microbiology Department, Ankara Yildirim Beyazit University, Ataturk Training & Research Hospital, Ankara, Turkey.
[cc]Infectious Diseases Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina.
[dd]Great West Reference centers for Complex Bone and Joint Infections (CRIOGO), France.
[ee]Service of Infectious Diseases, Hospital Clínic, University of Barcelona, Barcelona, Spain.

1
2

Collaborators:

Anne Gougeon, Harold Common, Anne Méheut, Joan Gomez-Junyent, Majd Tarabichi, Aybegum Demirturk, Taiana Ribeiro, Emerson Honda, Giancarlo Polesello, Paul Jutte, Joris Ploegmakers, Claudia Löwik, Guillem Bori, Laura Morata, Luis Lozano, Antonio Blanco García, Mikel Mancheño,

Fernando Chaves, David Smolders, Phongsakone Inthavong, Marc Digumber, Bernadette Genevieve Pfang, Eduard Tornero, Encarna Moreno, Ulrich Nöth, Cynthia Rivero, Pere Coll, Xavier Crusi, Isabel Mur, Juan Dapás, Pierre Tattevin, Jaime Esteban, Matthew Scarborough.

Corresponding author. Marjan Wouthuyzen-Bakker, internist-infectiologist, University Medical Center Groningen, Department of Medical Microbiology and Infection Prevention, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands
email: m.wouthuyzen-bakker@umcg.nl , tel: + 31 50 361 61 61, fax: + 31 50 361 9105

Highlights

- Late acute prosthetic joint infection (PJI) treated with surgical debridement and implant retention have a high failure rate, especially when caused by *S. aureus*.
- The exchange of mobile components during surgical debridement is the most potent predictor for treatment success.
- Preoperative risk factors for failure are: fracture as indication for the prosthesis, rheumatoid arthritis, an age above 80 years, male gender, chronic obstructive pulmonary disease, and a C-reactive protein >150 mg/L at baseline.
- Treatment strategies for late acute PJIs should be individualized according to the preoperative risk for failing and the microorganism causing the infection.

ABSTRACT

Objectives: Debridement, antibiotics and implant retention (DAIR) is the recommended treatment for all acute prosthetic joint infections (PJI), but its efficacy in patients with *late* acute (LA) PJI is not well described. *Methods*: Patients diagnosed with LA PJI between 2005 and 2015 were retrospectively evaluated. LA PJI was defined as the development of acute symptoms (≤ 3 weeks) occurring ≥ 3 months after arthroplasty. Failure was defined as: i) the need for implant removal, ii) infection related death, iii) the need for suppressive antibiotic therapy and/or iv) relapse or reinfection during follow-up. *Results*: 340 patients from 27 centers were included. The overall failure rate was 45.0% (153/340). Failure was dominated by *Staphylococcus aureus* PJI (54.7%, 76/139). Significant independent preoperative risk factors for failure according to the multivariate analysis were: fracture as indication for the

prosthesis (odds ratio (OR) 5.4), rheumatoid arthritis (OR 5.1), age above 80 years (OR 2.6), male gender (OR 2.0) and C-reactive protein >150 mg/L (OR 2.0). Exchanging the mobile components during DAIR was the strongest predictor for treatment success (OR 0.35). *Conclusion:* LA PJIs have a high failure rate. Treatment strategies should be individualized according to patients' age, comorbidity, clinical presentation and microorganism causing the infection.

Keywords

Prosthetic joint infection; Acute; Hematogenous; Risk factors, failure

INTRODUCTION

Prosthetic joint infections (PJI) can be subdivided into early post-surgical, chronic and late acute infections, the latter being considered to be mostly hematogenous of origin [1]. These subdivisions have been introduced to identify patients in whom the infected prosthesis can be debrided and retained (in case of acute infections) and to identify those in whom the infected prosthesis should be removed (in case of chronic infections). Despite these well-recognized categories of PJIs in literature, specific data on the clinical outcome of patients with a late acute infection is scarce. Several studies indicate that late acute PJIs have a higher failure rate compared to early acute (post-surgical) infections, especially when the infection is caused by *Staphylococcus aureus* (*S. aureus*) [2-8]. Some studies show higher failure rates in late acute PJIs caused by other microorganisms than *S. aureus* as well [9-10], but this has been discarded by others [11-13]. Current guidelines recommend the same surgical (debridement and implant retention (DAIR)) and antimicrobial strategy for both early and late acute infections [14], but late acute PJIs may require a different treatment approach. More evidence on the clinical outcome and identification of risk factors for failure in a larger cohort of patients is important to optimize treatment for this specific patient group. Therefore, we performed a large multicentre observational study to describe clinical outcome and risk factors for failure in late acute PJI treated with DAIR. We hypothesized that late acute PJIs have a high failure rate, especially when caused by *S. aureus*.

MATERIAL AND METHODS

Study design and inclusion criteria

We performed an international multicenter retrospective observational study in which data of all consecutive patients with a late acute PJI between January 2005 and December 2015 were collected. All patients who underwent surgical debridement according to the surgical records were retrospectively evaluated. If centers were not able to provide cases during the complete study period, a minimum of at least 10 consecutive cases was required to participate in the study. In each center, all DAIR procedures performed within the studied period according to the surgical records were evaluated, and only cases that met the strict definition of late acute PJI were included. Late acute PJI was defined as patients, with a prior history of normal function of the index arthroplasty, who developed a sudden onset of symptoms and signs of a PJI, such as acute pain and/or swelling of the prosthetic joint, more than 3 months after the implantation. Patients with a sinus tract and/or symptoms existing for longer than 3 weeks before surgical debridement were excluded from the analysis. Informed consent was retrieved when required by the ethics committee of the participating center. A PJI was defined according to the diagnostic criteria described by the Musculoskeletal Infection Society (MSIS) [15]. Multiple variables on patient characteristics, clinical presentation, medical microbiology results, surgical & antibiotic treatment and outcome were collected and analyzed.

Clinical outcome

Failure was defined as: i) the need for prosthesis removal due to persistent or recurrent clinical signs of infection (one or two-stage exchange, amputation, Girdlestone for hips or arthrodesis for knees) due to persistent clinical signs of infection, ii) the need for suppressive antibiotic therapy because of persistent clinical or biochemical signs of infection, iii) a relapse of infection with the same microorganism during follow-up, iv) a reinfection with a different microorganism than the initial infection during follow-up, or v) death due to the infection.

PJI related death was defined as death that occurred during (antibiotic) treatment with no other alternative explanation than an uncontrolled infection. The need for a second debridement during antibiotic therapy was not considered as failure. Patients in whom antibiotic suppressive therapy was prescribed for other reasons than persistent signs of infection (e.g. because this was routine practice of the participating hospital and/or because the patient had severe comorbidity and was therefore, not eligible for future surgeries) were excluded. Failure was subsequently categorized into *early failure*: persisting or reappearance of symptoms of infection during antibiotic treatment, and *late failure*: reappearance of symptoms of infection after finishing antibiotic treatment. *Complete remission* was considered in patients with a retained and functional implant after 2 years of follow-up. A functional implant was defined as the ability to walk without pain.

Statistical analysis

A Chi-square test (or a Fisher exact-test when appropriate) was used to analyze the difference between groups for categorical variables, and a student t-test (or Mann Witney U test when data was not normally distributed) for continuous variables. A Kaplan Meier survival curve with a cox-regression analysis was used to evaluate failure rate in time. Possible risk factors for failure were selected and analyzed using univariate analysis by Pearson's correlation. Variables with a significance level of < 0.2 were analyzed in a binary multivariate logistic regression model. A separate CART (classification and regression tree) analysis was performed to assess which variable was the most potent in predicting treatment outcome. All variables were tested for multicollinearity and additionally analyzed in a cox regression analysis. Preoperative variables with the highest odds ratio (OR) in the multivariate logistic regression model were included in a risk score, in which the beta coefficient of each variable served as an indicator for the height of the score. A subanalysis was performed for early and

late failure. In the analysis of early failure, late failures were considered as non-failures and included as such. All analyses were two-tailed and p-values < 0.05 were considered as statistically significant. Data were presented as mean ± Standard Deviation (SD) when data was normally distributed or median ± Inter Quartile Range (IQR) when data was not normally distributed. Statistical analysis was performed using SPSS, version 23.0 (SPSS Inc., Chicago, IL).

RESULTS

Characteristics of late acute PJI

A total of 340 cases were included in the analysis. From the total cohort, 247 out of 340 cases (72.6%) had a PJI of the knee. Isolated microorganism(s) on patient level are shown in Table 1. Surprisingly, coagulase negative staphylococci (CoNS) were isolated in 30 cases (8.8%), including 24 monomicrobial infections. After exclusion of *S. lugdunensis* (n=4), a pathogen with a higher virulence compared to other CoNS, 1 out of 20 CoNS PJIs had bacteremia (bloodcultures taken in 10 out of 20 cases), and none of them was diagnosed with endocarditis. In 170 out of 340 cases (50%) a source of the PJI was identified: i) skin infection (n=62, 36.5%), ii) dental procedure (n=18, 10.6%), iii) recent surgery (n=24, 14.1%), or iv) other (n=66, 38.8%). A preceding skin infection was described in 35/139 (25.2%) of *S. aureus* and in 22/97 (22.7%) of streptococcal infections. In gram-negative PJIs, recent surgery or another source than skin infection, was marked in 21 out of 50 cases (42%).

Failure rate and clinical outcome

The overall failure rate of late acute PJI was 45.0% (153/340). With a limited number of cases, failure rate was highest in PJI caused by *Enterococcus* species (72.7%, 8/11). There was no major difference in failure rate between *Enterococcus* species: treatment failed in 4 out of 5 cases (80%) with *E. faecium* and in 4 out of 6 cases (67%) with *E. faecalis*. The overall treatment failure was dominated by *S. aureus*, with a failure rate of 54.7% (76/139). The average failure with other microorganisms was around 40% (CoNS 40.0% (12/30), *Streptococcus* species 37.1% (36/97), gram-negatives 36.0% (18/50)). Patients with an unidentified source of infection showed a trend towards a higher failure rate (58.8%, 90/184) compared to those with an identified source of infection (41.2%, 63/156) (p 0.12). The percentage of failure in time according to the Kaplan-Meier survival curve is depicted in Figure 1.

Early failure occurred in 53.5% of failed cases (82/153), which mostly resulted in the need for implant removal (73.0%, 60/82) and in death due to the infection (13.4%, 11/82). The median time to failure during antibiotic therapy was 26 days (IQR 12 – 89). *Late* failure occurred in 46.5% of cases (71/153) and was mostly due to a relapse of infection with the same microorganism during follow-up (63.3%, 45/71), followed by reinfection with another microorganism (11.2%, 8/71). The remaining patients were put on suppressive antibiotic therapy because of persistent signs of inflammation and/or had a relapse of infection without an identified microorganism. The median time to failure after finishing antibiotic therapy was 6 months (IQR 4 – 11), in which 81.1% of patients failed within the first year after DAIR. The median follow-up of non-failures was 25.0 months (IQR 11 – 31). Seventy-two of the non-failures had a follow-up of 2 years, in whom complete remission was achieved in 75% (54/72).

Antibiotic treatment

The median days of intravenous (IV) antibiotic treatment was higher in failures compared to non-failures (22 days (IQR 12 – 42) versus 19 days (IQR 10 – 34) respectively, p 0.007). To analyze the effect of the total duration of IV and oral antibiotic treatment, *early* failures were excluded from the analysis. The rate of *late* failure was the same for those treated for less than 60 days (28.5%, 51/179) compared to those treated for more than 60 days (25.3%, 20/79) (p 0.56).

To exclude empirical antibiotic treatment, the type of antibiotic was only analyzed if prescribed for more than five days (Supplementary Table 2). For staphylococcal infections in whom data on the oral regimen was available, the failure rate was 49.3% (66/134) when rifampin was added versus 67.7% (21/31) when rifampin was not added to the antibiotic regimen (p 0.06). In addition, failure rate was significantly lower when rifampin was combined with a fluoroquinolone compared to other regimens (failure rate 45.5% (46/101) versus 64.1% (41/64), respectively, p 0.02). In the rifampin treated cases, there was no significant difference in failure rate in fluoroquinolone-based regimens compared to other antibiotics (46.0% (46/100) vs 58.8% (20/34), respectively, p 0.20). For streptococci, failure rate was 22.7% (5/22) when rifampin was added versus 42.5% (31/73) when rifampin was not added to the antibiotic regimen (p 0.13). With a limited number of gram-negative PJIs analyzed, the use of fluoroquinolones was not associated with treatment success in our analysis (failure rate of 34.3% (12/35) when using a fluoroquinolone versus 38.5 % (5/13) when using another antibiotic regimen, p 0.79).

Risk factors for failure

Table 2 shows the results of the univariate and multivariate binary logistic regression analysis in identifying risk factors for failure. From the total of 340 cases, all variables were complete without missing data in 232 cases and were included in the final model. Patients in whom no

blood cultures were obtained were considered as blood culture negative. The results of the multivariate analysis for other variables did not change when the blood culture variable was omitted from the analysis. The Hosmer and Lemeshow test had a p-value of 0.89, indicating that the model was adequate, with a predicting capacity of 71.1% according to the classification table.

Male gender, age above 80 years, rheumatoid arthritis (RA), fracture as indication for the prosthesis, C-reactive protein (CRP) above 150 mg/L, infection caused by *S. aureus* and the use of local antibiotics were all significant independent variables for failure in the multivariate analysis. Local antibiotic therapy mainly consisted of gentamicin beads or gentamicin sponges. There were no significant clinical differences between patients who were treated with local antibiotics compared to patients in whom it was withheld (data not shown), with the exception of the American Society of Anesthesiologist (ASA) classification score, which was higher in the local antibiotic group (ASA score ≥ 3 in 66.7% (20/30) versus 44.3% (102/230) respectively, p 0.02). With an OR of 2.9, COPD was also associated with a higher failure rate, although it did not reached statistical significance. Cox regression analysis showed the same predictors for failure. Analysis on multicollinearity revealed that COPD was accompanied by a higher prevalence of ischemic heart disease and heart failure. Exchanging the mobile components during DAIR was the only variable that was independently associated with treatment success. In addition, according to the CART analysis, exchanging the mobile components was the most potent variable in predicting treatment outcome.

Multivariate analysis showed that COPD, RA, CRP above 150 mg/L and *Enterococcus* species were significant independent predictors for *early* failure, while *S. aureus* was the only predictor for *late* failure (Supplementary Table 1).

Based on the results of the multivariate binary logistic regression, a risk score was developed, by using the preoperative variables that were associated with failure. In addition, as the

possibility to exchange the mobile components can be known preoperatively as well, the protective effect of exchanging the mobile components during DAIR was also included (Figure 2A). Because failure was dominated by *S. aureus*, a separate analysis was performed for the presence or absence of *S. aureus* (Figure 2B-C). Our results indicate that the preoperative model has the strongest predictive value for failure in PJIs caused by other microorganisms than *S. aureus*. In *S. aureus* PJI in whom mobile components were exchanged during DAIR, the rate of failure decreased from 47.1% to 36.6% when patients were treated with a fluoroquinolone in combination with rifampin.

Blood culture positive versus blood culture negative cases

Since cases with positive blood cultures are considered as the 'classical' late acute / hematogenous infections, we performed an additional analysis on blood culture positive versus proven blood culture negative cases. Table 3 shows the clinical differences between both groups. From the 259 cases in whom blood cultures were obtained, 42% (109/259) were blood culture positive. The rate of bacteremia was higher in hip PJIs and in implants of more than 2 years of age, and was more often associated with fever, infections caused by *S. aureus* and endocarditis. Echocardiography was performed in 72.5% of cases with *S. aureus* bacteremia (50/69). In the majority, this mainly comprised transthoracic echocardiography (53.6%). Endocarditis was diagnosed in 10% of cases (7/69). The overall failure rate was 15% higher in blood culture positive cases and was mostly ascribed to early failure (p 0.01) (Supplementary Table 1). From the failures in the blood culture positive group, 9 out of 61 cases (14.8%) died because of the infection. All of these 9 cases, with the exception of one, were diagnosed with endocarditis.

DISCUSSION

Due to the low incidence of late acute PJIs [16], clinical data and specific treatment recommendations for this subgroup of patients is limited. By the effort of many centers involved, we were able to describe the clinical characteristics of late acute PJIs, evaluate its outcome, and identify risk factors for failure. In a large cohort of 340 late acute PJIs treated with DAIR, we demonstrated a failure rate of 45%, in which treatment failure was most prominent when caused by *S. aureus*.

The high failure rate observed in our study may partly be explained by: i) The presence of an unidentified source of infection in case of bacteremia. Although not statistically significant, an unidentified source of infection was associated with a higher failure rate in our study. Endocarditis may have been underdiagnosed in our study, as a transesophageal echocardiography was not performed in all *S. aureus* bacteremias. Thus, continuous seeding of bacteria to the prosthetic joint with the development of biofilm may be the cause of failure in these cases. Indeed, we demonstrated that a relapse of infection during follow-up was mostly caused by *S. aureus*, which supports this hypothesis. However, it is important to note that the reported incidence of endocarditis in *S. aureus* bacteremia in literature is comparable to our study [17], and failure rate was still 40% in blood culture negative cases. ii) A previously unrecognized chronic PJI. Although we held on to a clear definition of a sudden onset of symptoms in a priorly asymptomatic joint, we cannot completely rule out that chronic PJIs that deteriorated acutely also comprised a small part of the cohort. CoNS were identified in a limited number of patients and these microorganisms are not common pathogens for causing acute infections. Indeed, most of these cases were blood culture negative and were not diagnosed with endocarditis, which makes an acute infection in these cases unlikely. However, the failure rate in CoNS was not higher than in others (40%), and patients with a proven hematogenous infection had a higher failure rate compared to blood

culture negative cases iii) Mobile components were not exchanged in almost half of our studied cohort. As the CART analysis showed that this is the most potent variable for predicting failure, treatment success may be substantially higher when mobile exchange was performed in all cases. The low number of exchange may be due to the fact that the study extends over ten year time period and only in recent years, the importance of this surgical technique became clear. In addition, mobile components are not available in acute settings in some centers. However, even with the exchange of mobile components, overall failure rate was still 36%, and even higher in case of *S. aureus* infections.

At the moment, a DAIR procedure is the recommended surgical approach for all acute PJIs with stable implants and susceptibility to potent anti-biofilm regimens [14]. Our data suggest that a DAIR should be reconsidered in late acute PJIs for certain patient categories. As previously mentioned, especially *S. aureus* PJI has a high risk of failure, especially when mobile components cannot be exchanged and treatment with a rifampin-based regimen is not possible. Failure rate was much lower in a study performed by Tande et. al., in which late acute PJI caused by *S. aureus* was treated with revision surgery or if the DAIR was followed by chronic suppressive antibiotic therapy [8]. Therefore, identifying the causative microorganism and its susceptibility pattern preoperatively may be helpful to choose the best surgical approach in an acute setting. To elaborate, studies have shown that Gram staining of synovial fluid has a poor sensitivity in diagnosing PJI, but its value is mostly evaluated in chronic cases, and may be more useful and sensitive in acute infections [18]. Unfortunately, early molecular detection does not show any benefit so far in acute PJIs, but its diagnostic accuracy maybe optimized in upcoming years [19]. For late acute PJIs caused by another microorganism than *S. aureus*, the CRIME80 score could be useful in identifying high-risk patients. According to our analysis, patients who received a prosthetic implant because of a fracture and patients with rheumatoid arthritis are at highest risk to fail. Previous studies have

shown, that these variables are also strongly correlated with failure in early postsurgical and chronic PJIs [5, 11, 20]. In addition, our data indicate that patients with male gender, COPD, a CRP above 150 mg/L at presentation and an age above 80 years are also more prone to fail. Accordingly, a DAIR procedure is probably not advisable in late acute PJI with a high a priori chance of failure. In addition, some studies suggest that revision surgery applied as salvage therapy after DAIR failure is associated with poorer outcome [21-22]. Therefore, our results suggest the need for revision surgery as a first surgical approach .

Non-surgical strategies to increase the chance of treatment success seem limited. In our study, the addition of rifampin in staphylococcal infections, especially when combined with a fluoroquinolone, improved treatment outcome, which is in accordance with previous findings. [2,23]. A longer duration of intravenous antibiotic treatment and/or the use of local antibiotics was associated with a higher failure rate, but this may be due to selection bias as antibiotic treatment is most often intensified in more severe infections. Indeed, we found a higher ASA classification score in patients who received local antibiotics compared to patients in whom local antibiotics was withheld. Therefore, the exact value of local antibiotics, the type of antibiotic, the use of chronic suppressive therapy and certain antibiotic combinations should be addressed in future studies, ideally in a randomized controlled study design. For this reason, we want to emphasize that our results on the effect of antibiotic treatment on clinical outcome should be evaluated in light of the aforementioned limitations and interpreted with caution.

In conclusion, late acute PJIs treated with DAIR have a high failure rate, especially when caused by *S. aureus* and without the exchange of mobile components. Treatment strategies should be tailored and optimized to improve the outcome. This should be addressed in future studies.

FUNDING

No funding was obtained for this study.

CONFLICT OF INTEREST

None of the authors declared any conflict of interest.

REFERENCES

1. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med **2004**; 351(16):1645-54.
2. Lora-Tamayo J, Murillo O, Iribarren JA et al. A large multicenter study of methicillin susceptible and methicillin-resistant *Staphylococcus aureus* prosthetic joint infections managed with implant retention. Clin Infect Dis **2013**; 56(2):182-94.
3. Vilchez F, Martinez-Pastor, Garcia-Ramiro S et al. Efficacy of debridement in hematogenous and early post-surgical prosthetic joint infections. Int J Artif Organs **2011**; 34(9):863-9.
4. Rodriguez D, Pigrau C, Euba G et al. Acute haematogenous prosthetic joint infection: prospective evaluation of medical and surgical management Clin Microbiol Infect **2010**; 16(12):1789-95.
5. Tornero E, Morata L, Martinez-Pastor JC et al. KLIC-score for predicting early failure in prosthetic joint infections treated with debridement, implant retention and antibiotics. Clin Microbiol Infect **2015**; 21:9-17.
6. Cobo J, Miguel LGS, Euba G et al. Early prosthetic joint infection : outcomes with

debridmeent and implant retention followed by antibiotic therapy. Clin Micrbiol Infect **2011**; 1:1632-37.

7. Vilchez F, Martinez-Pastor JC, Garcia-Ramiro S et al. Outcome and predictors of failure in early post-surgical prosthetic joint infections due to *Staphylococcus aures* treated with debridment. Clin Micrbiol Infect **2011**; 17:439-44.
8. Tande AJ, Palrai BR, Osmon DR et al. Clinical presentation, risk factors, and outcomes of hematogenous prosthetic joint infection in patients with *Staphylococcus aureus* bacteremia. Am J Med **2016**; 129(2):e11-20.
9. Puhto AP, Puhto T, Niinimäki T et al. Predictors of treatment outcome in prosthetic joint infections treated with prosthesis retention. Int Orthop **2015**; 39(9):1785-91.
10. Koh IJ, Han SB, In Y et al. Open debridement and prosthesis retention is a viable treatment option for acute periprosthetic joint infection after total knee arthroplasty. Arch Orthop Trauma Surg **2015**; 135(6):847-55.
11. Lora-Tamayo J, Senneville É, Ribera A et al. The Not-So-Good Prognosis of Streptococcal Periprosthetic Joint Infection Managed by Implant Retention: The Results of a Large Multicenter Study. Clin Infect Dis **2017**; 64(12):1742-52.
12. Tornero E, Senneville E, Euba G et al. Characteristics of prosthetic joint infections due to Enterococcus sp. and predictors of failure: a multi-national study. Clin Microbiol Infect **2014**; 20:1219-24.
13. Rodriguez-Pardo D, Pigrau C, Lora-Tamayo J et al. Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study. Clin Microbiol Infect **2014**; 20:O911-19.
14. Osmon DR, Berbari EF, Berendt AR et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the infectious diseases society of America. Clin Infect Dis **2013**; 56(1):1-25.

15. Parvizi J and Gehrke T. Definition of periprosthetic joint infection. J Arthroplasty **2014**; 29(7):1331.
16. Huotari K, Peltola M, Jämsen E et al. The incidence of late prosthetic joint infections: a registry-based study of 112,708 primary hip and knee replacementes. Acta Orthop **2015**; 86(3):321-25.
17. Kaasch AJ, Barlow G, Edgeworth JD et al. Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies. J Infect **2014**; 68(3):242-51.
18. Ouyang Z, Zhai Z, Qin A et al. Limitations of gram staining for the diagnosis of infections following total hip or knee arthroplasty. Exp Ther Med **2015**; 9(5):1857-64.
19. Villa F, Toscano M, De Vecchi E et al. Reliability of a multiplex PCR system for diagnosis of early and late prosthetic joint infections before and after broth enrichment. Int J Med Microbiol **2017**; 307(6):363-70.
20. Hsieh PH, Huang KC, Shih HN. Prosthetic joint infection in patients with rheumatoid arthritis: an outcome analysis compared with controls. PLoS One **2013**; 26;8(8):e71666.
21. Gardner J, Gioe TJ, Tatman P. Can this prosthesis be saved? Clin Orthop Relat Res **2011**; 469:970-76.
22. Sherrel JC, Fehring TK, Odum S et al. Fate of two-stage reimplantation after failed irrigation and debridement for periprosthetic knee infection. Clin Orthop Relat Res **2011**; 469:18-25.
23. El Helou OC, Berbari EF, Lahr BD et al. Efficacy and safety of rifampin containing regiment for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis **2010**; 29(8):961-7.



Figure 1. Kaplan-Meier survival curve late acute PJI treated with DAIR.
Survival is defined as treatment success, as described in the material and method section. *A.* Overall survival (n=340). *B.* Survival categorized in PJI caused by *S. aureus* (n=139, including 10 cases with polymicrobial infection), *Enterococcus* spp (n=11 including 4 cases with polymicrobial infection) and other microorganisms (n=190). *C.* Survival according to the exchange of mobile components during debridement. In the survival group (n=187), 44 cases (23.5%) had a follow-up of less than 12 months.

395

Isolated microorganism(s)	n (%)
Gram positives	**247 (72.7)**
Staphylococcus aureus	
Methicillin susceptible *S. aureus*	113 (33.2)
Methicillin resistant *S. aureus*	16 (4.7)
Staphyloccocus lugdunensis	4 (1.2)
Other coagulase negative staphylococci	20 (5.8)
Enterococcus species	7 (2.1)
Streptococcus species	
Streptococcus pyogenes	20 (5.9)
Streptococcus dysgalactiae	15 (4.4)
Streptococcus agalactiae	18 (5.3)
Streptococcus pneumoniae	5 (1.5)



396

397
398
399 **Figure 2**. Failure rate according to CRIME80 risk score.
400 The risk score was developed according to the results of the multivariate bivariate regression analysis, including
401 preoperative variables that were independently associated with failure, and exchange of mobile components as a
402 predictor for treatment success as depicted in Table 1. A. Overall failure (n=340). B. Failure rate in S.aureus
403 negatives cases (n=201). C. Failure rate in S. aureus positive cases (n=139). COPD: Chronic Obstructive
404 Pulmonary Disease, CRP: C-Reactive Protein.
405
406 **Table 1**. Isolated microorganisms.
407 *Other: *Salmonella* spp (3), *Morganella morganii* (3), *Serratia marcescens* (2), *Acinetobacter baumannii* (1),
408 *H. influenza* (1), *Helicobacter cinaedi* (1), *Campylobacter fetus* (1).

Streptococcus anginosus	4 (1.5)					
Group viridans streptococci, not specified	11 (4.2)					
Group G streptococci, not specified	7 (2.7)					
Other *Streptococcus* species	7 (2.7)					
Gram negatives	**40 (11.8)**					
Escherichia coli	14 (4.1)					
Klebsiella pneumoniae	5 (1.5)					
Enterobacter cloacae	4 (1.2)					
Pseudomonas aeruginosa	4 (1.2)					
Proteus mirabilis	1 (0.3)					
Other*	12 (3.5)					
Anaerobes	**2 (0.6)**					
***Candida* species**	**1 (0.3)**					
Polymicrobial	**25 (7.4)**					
Including *S. aureus*	10 (2.9)					
Including *Enterococcus* species	4 (1.2)					
Including *Streptococcus* species	10 (2.9)					
Including Gram negatives	11 (3.2)					
Including *Candida* species	3 (0.9)					
Culture negative	**25 (7.4)**					

Table 2. Risk factors for failure.
*Variables included in the multivariate binary logistic regression analysis. [1]Patients in whom no bloodcultures were obtained were considered as bloodculture negative

	Non-failures	Failures	Unadjusted OR (95% CI)	p-value	Adjusted OR (95% CI)	p-value
Baseline characteristics						
Gender, male	47.6% (89/187)	56.2% (86/153)	1.41 (0.92 – 2.17)	0.11*	2.02 (1.05 – 3.89)	**0.04**
Age > 80 years	17.6% (33/187)	26.1% (40/153)	1.65 (0.98 – 2.78)	0.06*		
BMI > 30	51.2% (66/129)	45.8% (44/96)	0.81 (0.47 – 1.37)	0.43	2.60 (1.15 – 5.91)	**0.02**
ASA classification ≥ III	46.9% (76/162)	50.8% (64/126)	1.12 (0.73 – 1.86)	0.52		
Medical history						
Hypertension	59.7% (111/186)	59.5% (91/153)	0.99 (0.64 – 1.53)	0.97		
Ischemic heart disease	10.2% (19/187)	14.4% (22/153)	1.48 (0.77 – 2.86)	0.24		
Heart failure	8.6% (16/187)	9.9% (15/152)	1.12 (0.56 – 2.45)	0.68		
Diabetes Mellitus	23.0% (43/187)	27.5% (42/153)	1.19 (0.73 – 1.92)	0.49		
COPD	8.0% (15/187)	12.4% (19/153)	1.63 (0.79 – 3.32)	0.18*	2.9 (0.99 – 8.68)	**0.05**
Chronic renal insufficiency	8.6% (16/187)	6,5% (10/153)	0.75 (0.33 – 1.69)	0.49		
Liver cirhosis	2.7% (5/187)	3.9% (6/153)	1.49 (0.44 – 4.97)	0.52		
Active malignancy	7.5% (14/187)	9.8% (15/153)	0.65 (0.06 – 7.22)	0.04*	1.76 (0.59 – 5.35)	0.31
Rheumatoid arthritis	3.7% (7/187)	13.1% (20/153)	3.87 (1.59 – 9.41)	0.001*	5.13 (1.08 – 24.34)	**0.04**
Medication						
Oral anticoagulant	16.2% (30/185)	20.5% (31/151)	1.34 (0.77 – 2.33)	0.31		
Immune-suppressive drugs	8.0% (15/187)	15.7% (24/153)	2.13 (1.07 – 4.23)	0.03*	0.53 (0.17 – 1.63)	0.27
Characteristics infected implant						
Knee	74.9% (140/187)	69.9% (107/153)	0.78 (0.48 – 1.26)	0.31		
Indication prosthesis: fracture	2.8% (5/177)	8.8% (12/136)	3.32 (1.14 – 9.69)	0.02*	5.39 (1.42 – 20.46)	**0.01**
Revision prosthesis	23.8% (44/185)	34.0% (52/153)	1.65 (1.03 – 2.66)	0.04*	1.21 (0.60 – 2.45)	0.60
Tumor prosthesis	4.4% (8/181)	4.1% (6/145)	0.93 (0.32 – 2.75)	0.90		
Cemented stem	75.9% (107/141)	74.5% (79/106)	0.93 (0.52 – 1.67)	0.81		
Age of the implant > 2 years	59.4% (111/187)	68.6% (105/153)	1.49 (0.96 – 2.35)	0.08*	0.96 (0.49 – 1.89)	0.90
Clinical presentation						
Duration of symptoms > 10 days	17.1% (32/187)	25.5% (39/153)	1.66 (0.98 – 2.80)	0.06*	1.21 (0.54 – 2.74)	0.64
Temperature > 38.5°C	18.0% (32/178)	25.2% (38/151)	1.53 (0.90 – 2.61)	0.11*	1.84 (0.84 – 4.03)	0.13
Physical signs of inflammation	84.2% (149/177)	78.2% (115/147)	0.68 (0.38 -1.19)	0.17*	1.81 (0.74 – 4.45)	0.20
CRP > 150 mg/L	57.7% (101/175)	63.7% (93/146)	1.29 (0.82 – 2.02)	0.06*	2.00 (1.04 – 3.86)	**0.04**
Leucocytes > 15 cells/ µL	38.5% (67/174)	46.2% (66/143)	0.93 (0.49 – 1.74)	0.39		
Bacteremia[1]	25.8% (48/186)	39.9% (61/153)	1.91 (1.20 – 3.02)	0.005*	0.96 (0.45 – 2.05)	0.91
Endocarditis	2.7% (5/187)	5.2% (8/153)	2.00 (0.64 – 6.27)	0.22		
Causative micro-organism						
Staphylococcus aureus	34.8% (65/187)	49.7% (76/153)	1.85 (1.19 – 2.86)	0.005*	3.52 (1.78 – 6.96)	**< 0.001**
Methicillin resistant	4.3% (8/187)	7.2% (11/153)	1.73 (0.68 – 4.42)	0.25		
Enterococcus species	1.6% (3/187)	5.2% (8/153)	3.38 (0.88 – 12.98)	0.06*	3.71 (0.64 – 21.59)	0.14
Surgical techniques DAIR						
Exchange of mobile components	61.5% (112/182)	45.5% (64/141)	0.52 (0.33 – 0.81)	0.004*	0.35 (0.18 – 0.67)	**0.002**
> 1 DAIR	8.0% (15/187)	14.4% (22/153)	1.93 (0.96 – 3.86)	0.06*	2.30 (0.88 – 6.02)	0.09
Use of local antibiotics	7.8% (13/167)	12.6% (18/143)	1.71 (0.81 – 3.62)	0.16*	3.78 (1.39 – 10.22)	**0.009**

cases. BMI: Body Mass Index, ASA: American Society of Anesthesiologist, COPD: Chronic Obstructive Pulmonary Disease, CRP: C-Reactive Protein, DAIR: Debridement, Antibiotics and Implant Retention.

Table 3. Characteristics blood culture positive and bloodculture negative cases (n=259). Cases in whom bloodcultures were not obtained were excluded from the analysis (n=81).

	Blood culture positive (n=109)	Blood culture negative (n=150)	p-value
Characteristics infected implant			
Knee	58.7% (64/109)	78.0% (117/150)	**0.001**
Revision prosthesis	24.1% (26/108)	30.7% (46/150)	0.23
Cemented stem	73.2% (52/71)	82.7% (81/98)	0.14
Age of the implant > 2 years	78.0% (85/109)	60.7% (91/150)	**0.003**
Clinical presentation			
Duration of symptoms > 10 days	22.9% (25/109)	20.7% (31/150)	0.66
Temperature > 38.5°C	33.9% (37/109)	19.2% (28/146)	**0.007**
Physical signs of inflammation	67.0% (71/106)	87.5% (126/144)	**<0.001**
CRP > 150 mg/L	67.3% (68/101)	60.8% (87/143)	0.30
Endocarditis	10.1% (11/109)	1.3% (2/150)	**0.001**
Causative micro-organism			
Staphylococcus aureus	63.3% (69/109)	30.0% (45/150)	**<0.001**
Streptococcus species	24.3% (25/103)	33.3% (50/150)	0.14
Outcome			
Overall failure	56.0% (61/109)	41.3% (62/150)	**0.02**
Early failure	34.9% (38/109)	20.7% (31/150)	**0.01**
Late failure	21.1% (23/109)	20.7% (31/150)	0.85

Supplementary Table 1. Risk factors for early and late failure.
Results of multivariate binary logistic regression analysis for early failure (n=81) and late failure (n=72) in a total of 340 cases. *p-values <0.2 were included in the multivariate regression analysis.

	Non-failures	Early Failures	p-value	Adjusted OR (95% CI)	p-value	Non-failures	Late F
Baseline characteristics							
Gender, male	49.8% (129/259)	56.8% (46/81)	0.27	0.85		47.6% (89/187)	55.6%
Age > 80 years	20.8% (54/259)	23.5% (19/81)	0.62			17.6% (33/187)	29.2%
BMI > 30	50.9% (86/169)	42.9% (24/56)	0.30			51.2% (66/129)	50.0%
ASA classification ≥ III	44.5% (97/218)	61.4% (43/70)	0.01*	1.74 (0.84 – 3.60)	0.14	46.9% (76/162)	37.5%
Medical history							
Hypertension	58.5% (151/258)	63.0% (51/81)	0.48			59.7% (111/186)	55.6%
Ischemic heart disease	12.4% (32/259)	11.1% (9/81)	0.76			10.2% (19/187)	18.1%
Heart failure	8.1% (21/259)	12.5% (10/80)	0.23			8.6% (16/187)	6.9%
Diabetes Mellitus	24.3% (63/259)	27.2% (22/81)	0.76			23.0% (43/187)	27.8%
COPD	8.5% (22/259)	14.8% (12/81)	0.10*	4.26 (1.62 – 11.17)	**0.003**	8.0% (15/187)	9.7%
Chronic renal insufficiency	6.6% (17/259)	11.1% (9/81)	0.18*	1.14 (0.35 – 3.76)	0.83	8.6% (16/187)	1.4%
Liver cirrhosis	2.3% (6/259)	6.2% (5/81)	0.09*	0.98 (0.11 – 8.64)	0.98	2.7% (5/187)	1.4%
Active malignancy	7.3% (19/259)	12.3% (10/81)	0.16*	2.58 (0.79 – 8.37)	0.12	7.5% (14/187)	6.9%
Rheumatoid arthritis	5.0% (13/259)	17.3% (14/81)	< 0.001*	4.20 (1.11 – 15.85)	**0.03**	3.7% (7/187)	8.3%
Medication							
Oral anticoagulant	16.8% (43/256)	22.5% (18/80)	0.25			16.2% (30/185)	18.3%
Immune-suppressive drugs	9.3% (24/259)	18.5% (15/81)	0.02*	0.60 (0.16 – 2.19)	0.44	8.0% (15/187)	12.5%
Characteristics infected implant							
Knee	74.5% (193/259)	66.7% (54/81)	0.17			74.9% (140/187)	73.6%
Indication prosthesis: fracture	3.8% (9/239)	10.8% (8/74)	0.02*	0.86 (0.38 – 1.95)	0.72	2.8% (5/177)	6.5%
Revision prosthesis	27.2% (70/257)	32.1% (26/81)	0.40			23.8% (44/185)	36.1%
Tumor prosthesis	4.4% (11/249)	3.9% (3/77)	0.84			4.4% (8/181)	4.4%
Cemented stem	76.5% (143/187)	71.7% (43/60)	0.45			75.9% (107/141)	78.3%
Age of the implant > 2 years	62.2% (161/259)	67.9% (55/81)	0.35			59.4% (111/187)	69.4%
Clinical presentation							
Duration of symptoms > 10 days	20.8% (54/259)	21.0% (17/81)	0.98			17.1% (32/187)	30.6%
Temperature > 38.5°C	20.2% (50/248)	24.7% (20/81)	0.39			18.0% (32/178)	25.7%
Physical signs of inflammation	82.9% (204/246)	76.9% (60/78)	0.24			84.2% (149/177)	79.7%
CRP > 150 mg/L	58.2% (142/244)	67.5% (52/77)	0.14*	2.14 (1.01 – 4.54)	**0.05**	57.7% (101/175)	59.4%
Leucocytes > 15 cells/ µL	13.3% (32/241)	18.4% (14/76)	0.27			14.9% (26/174)	9.0%
Bacteremia[1]	27.9% (72/258)	45.7% (37/81)	0.003*	1.11 (0.54 – 2.31)	0.77	25.8% (48/186)	33.3%
Endocarditis	3.1% (8/259)	6.2% (5/81)	0.21			2.7% (5/187)	4.2%
Causative microorganism							
Staphylococcus aureus	40.2% (104/259)	45.7% (37/81)	0.38			34.8% (65/187)	54.2%
Methicillin resistant	5.4% (14/259)	6.2% (5/81)	0.79			4.3% (8/187)	8.3%
Enterococcus species	1.5% (4/259)	8.6% (7/81)	0.002*	16.0 (3.48 – 73.76)	**<0.001**	1.6% (3/187)	1.4%
Surgical techniques DAIR							
Exchange of mobile components	58.7% (145/247)	40.8% (31/76)	0.006*	0.43 (0.21 – 0.88)	**0.02**	61.5% (112/182)	50.8%
> 1 DAIR	9.7% (25/259)	14.8% (12/81)	0.19*	1.65 (0.59 – 4.58)	0.34	8.0% (15/187)	13.9%
Use of local antibiotics	9.0% (21/234)	13.2% (10/76)	0.29			7.8% (13/167)	11.9%

Supplementary Table 2. Oral antibiotic regimen.

	n (%)
S. aureus **(n=136)**	
Rifampin-based regimen	113 (83.1%)
- fluoroquinolone	88 (64.7%)
- cotrimoxazole	9 (6.6%)
- clindamycin	6 (4.4%)
- linezolid	9 (6.6%)
No rifampin-based regimen	23 (16.9%)
- fluoroquinolone	6 (4.4%)
- cotrimoxazole	2 (1.5%)
- clindamycin	5 (3.7%)
- linezolid	1 (0.8%)
Gram negatives (n=48)	
Fluoroquinolone	35 (72.9%)
Cotrimoxazole	2 (4.2%)
Amoxicillin/clavulanate	2 (4.2%)
Streptococcus **species (n=95)**	
Amoxicillin	55 (57.9%)
Clindamycin	12 (12.6%)
Linezolid	4 (4.2%)
Rifampin-based regimen	22 (23.1%)